PHASE Scientific Shines at IPVS 2025 with Breakthrough Urine-Based HPV Research

From October 23–26, 2025, the 37th Annual Conference of the International Papillomavirus Society (IPVS 2025), hosted by the International Papillomavirus Society (IPVS), was held in Bangkok, Thailand.
 

This year’s conference, themed “Ending HPV: Lessons Learned from HIV,” brought together 1,853 researchers, clinicians, and public health experts from 101 countries, focusing on the latest advances in HPV prevention, screening, treatment, and global health strategies.

The event, chaired by renowned expert Professor Praphan Phanuphak, featured three thematic sessions designed to offer a comprehensive academic platform covering basic science, clinical practice, public health, and epidemiological research, with the goal of strengthening global HPV-related disease prevention and control through scientific innovation.

PHASE is honored to present three pioneering abstracts

PHASE Scientiic, in collaboration with Peking University Shenzhen Hospital, were interested to the conference. We are honored to present three pioneering abstracts, reinforcing the transformative potential of our PHASiFY™-powered urine HPV test.

1. Abstract Number: 1777
   Abstract Title: DEVELOPMENT OF A URINE-BASED WORKFLOW TO DETECT METHYLATION MARKERS ASSOCIATED WITH CERVICAL INTRAEPITHELIAL NEOPLASIA ABNORMALITIES AND CERVICAL CANCER
2. Abstract Number: 1643
   Abstract Title: VERIFICATION OF A URINE HPV TESTING ASSAY WITH DNA PURIFICATION AND CONCENTRATION PROCESS
3. Abstract Number: 1207
   Abstract Title: CONSISTENCY OF URINE HPV TEST WITH A SEQUENCING-BASED HPV DNA GENOTYPING ASSAY

These studies demonstrate the clinical value and breakthrough potential of PHASE Scientific’s proprietary PHASiFY™ technology in cervical cancer prevention and control.

Dr. Ricky Chiu, Chaiman and CEO of PHASE Scientific

Dr. Pin Yin, Chief Scientific Officer (right) of PHASE Scientific & Chris Dulany, Commercialization Manager of PHASE Scientific Americas (left)

PHASiFY™ Concentration Technology Sets New Benchmark for Urine-Based HPV Testing
Following its appearances at the China Self-Sampling Cervical Cancer Screening Expert Symposium in March 2025 and the American Society for Colposcopy and Cervical Pathology (ASCCP) meeting, PHASE Scientific once again took the international stage, reinforcing its growing influence in the global HPV research community and its active role in advancing cervical cancer screening technologies.
 

At the conference, PHASE Scientific showcased its urine self-collection HPV test developed with PHASiFY™ concentration technology. This technology enables target HPV DNA in urine samples to be concentrated more than tenfold compared to industry gold standards. The test demonstrated a sensitivity of 93.42% for detecting cervical intraepithelial neoplasia grade 2 or higher (CIN2+) and over 98% concordance with physician-collected samples using the Roche Cobas 4800 HPV test. Led by the team at Peking University Shenzhen Hospital, this research was awarded the "Best Clinical Research Abstract" at the 2025 ASCCP Annual Meeting—one of the most prestigious honors in the field.

At the event, Dr. Ricky Chiu, Chairman & CEO and Dr. Peng Yin, Chief Scientific Officer of PHASE Scientific welcomed IPVS President-Elect Dr. Anna-Barbara Moscicki, engaging in in-depth discussions on HPV prevention and control.
 

International Experts Discuss the Future of Urine-Based HPV Screening

PHASE Scientific’s exhibition booth attracted significant attention from global experts, who engaged in deep discussions regarding the features and advantages of urine-based HPV testing.

Many experts agreed that urine collection, being non-invasive, convenient, and highly acceptable, represents an ideal sampling method that could significantly increase participation in cervical cancer screening programs among women. The highly efficient concentration method enabled by PHASiFY™ ensures strong consistency between urine-based and clinician-collected HPV test results, providing a solid foundation for the development of new screening standards and advancing cervical cancer prevention efforts.
 

Contributing to Global Cervical Cancer Prevention Goals

Through this prestigious conference, Phase Scientific not only demonstrated its technological strength and research achievements in HPV testing to the international academic community, but also established broader channels for exchange and collaboration with global experts. Looking ahead, Phase Scientific will continue to drive innovation and clinical translation, support increased coverage of cervical cancer screening, and actively contribute to the World Health Organization’s 2030 goal of 70% screening coverage—demonstrating the impact and commitment of Chinese enterprises in advancing global public health.